Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib
Open Access
- 1 May 2008
- journal article
- case report
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (5) , 1001-1006
- https://doi.org/10.1158/1535-7163.mct-07-2422
Abstract
Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor)–based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue. [Mol Cancer Ther 2008;7(5):1001–6]Keywords
This publication has 21 references indexed in Scilit:
- A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromeBlood, 2007
- BAY 43-9006 Inhibition of Oncogenic RET MutantsJNCI Journal of the National Cancer Institute, 2006
- RET tyrosine kinase signaling in development and cancerCytokine & Growth Factor Reviews, 2005
- Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingBlood, 2003
- Prognostic value of codon 918 (ATG?ACG)RET proto-oncogene mutations in sporadic medullary thyroid carcinomaInternational Journal of Cancer, 2001
- Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factorOncogene, 2000
- Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutationOncogene, 1999
- Mechanism of Ret Activation by a Mutation at Aspartic Acid 631 Identified in Sporadic PheochromocytomaBiochemical and Biophysical Research Communications, 1999
- Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogeneOncogene, 1997
- Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomasJournal of Clinical Endocrinology & Metabolism, 1995